Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Recent advances in malignant melanoma.

Victoria Atkinson^1,2,3

¹University of Queensland, Brisbane, Queensland, Australia.

Internal Medicine Journal

|October 11, 2017

Summary

New targeted therapies and immunotherapies have significantly improved survival for patients with advanced metastatic melanoma in Australia. These BRAF-targeted treatments and checkpoint inhibitors offer better outcomes for BRAF mutation-positive melanoma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Rapid-access oncodermatology is associated with reduced corticosteroid use and supports continuation of anticancer therapy after treatment-related cutaneous toxicity.

JAAD international·2026

Same author

Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Same author

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Outcomes of patients with unresectable or metastatic melanoma after cessation of immunotherapy following complete metabolic response or toxicities.

Internal medicine journal·2026

Same author

Second primary invasive cutaneous melanomas in Queensland over 4 decades.

The Journal of investigative dermatology·2026

Area of Science:

Oncology
Dermatology
Immunology

Background:

Metastatic melanoma incidence is high in Australia, with historically poor survival rates.
Advances in understanding melanoma oncogenes and the immune system have revolutionized treatment.
BRAF oncogene and immune checkpoint pathways are key targets in melanoma therapy.

Purpose of the Study:

To review the current standard of care for metastatic malignant melanoma.
To discuss the impact of novel targeted therapies and immunotherapies.
To highlight improvements in patient outcomes for metastatic melanoma.

Main Methods:

Review of current therapeutic strategies for metastatic melanoma.
Analysis of the impact of BRAF-targeted therapies.

Keywords:

BRAF inhibitor MEK inhibitor immune therapy melanoma

Related Experiment Videos

Evaluation of checkpoint inhibitor efficacy and tolerability.

Main Results:

BRAF-targeted therapies show significant improvements in response rates, disease control, and overall survival for BRAF mutation-positive patients.
Checkpoint inhibitors demonstrate improved response rates, duration of control, and overall survival.
These advancements represent a paradigm shift in metastatic melanoma treatment.

Conclusions:

Targeted therapies and immunotherapies have dramatically improved outcomes for metastatic melanoma.
Checkpoint inhibitors show promise and are being explored in other cancers.
The current standard of care has been significantly advanced by these novel treatments.